BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Receivables - Net data on file, last reported at $205.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 78.05% year-over-year to $205.2 million; the trailing twelve-month figure through Mar 2026 stood at $205.2 million (up 78.05% YoY), and the FY2025 full-year result was $139.4 million, up 2853.07% from the prior year.
• Receivables - Net grew to $205.2 million in Q1 2026, from $139.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $235.5 million in Q1 2024 to a low of $478000.0 in Q3 2024.
• A 5-year average of $58.6 million and a median of $17.1 million in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net slumped 92.34% in 2024 and soared 24276.15% in 2025, its largest moves.
• Tracing BBIO's Receivables - Net over 5 years: stood at $17.1 million in 2022, then plunged by 89.75% to $1.8 million in 2023, then soared by 169.67% to $4.7 million in 2024, then jumped by 2853.07% to $139.4 million in 2025, then jumped by 47.17% to $205.2 million in 2026.
• Business Quant data shows BBIO's Receivables - Net at $205.2 million in Q1 2026, $139.4 million in Q4 2025, and $116.5 million in Q3 2025.